Fennec Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 7, 2024
FENC 10.31.2024
Drug:PEDMARK-001 PEDMARK
Diseases:platinum-induced ototoxicity
Date of Upcoming Event:2024-11-07
Name of Upcoming Event:Conference Call & Webcast
About Gravity Analytica
Recent News
- 12.20.2024 - FENNEC PHARMACEUTICALS ANNOUNCES PEDMARQSI POSITIVE RECOMMENDATION BY NICE FOR THE PREVENTION OF CISPLATIN-INDUCED HEARING LOSS IN ENGLAND AND WALES
- 12.20.2024 - Fennec Pharmaceuticals Announces Pedmarqsi® Positive Recommendation by NICE for the Prevention of Cisplatin-Induced Hearing Loss in England and Wales
- 12.19.2024 - FENNEC PHARMACEUTICALS ANNOUNCES EARLY PARTIAL REPAYMENT OF ITS OUTSTANDING CONVERTIBLE DEBT FACILITY WITH PETRICHOR HEALTHCARE CAPITAL MANAGEMENT
Recent Filings
Conference Call & Webcast Detail:
| Date: | |
| Time: | |
| Link: | https://edge.media-server.com/mmc/p/e6my278s |
To access the conference call, dial 888-596-4144 or 646-968-2525 internationally and referencing the conference access ID: 6896851. To access the live webcast link, log ontowww.fennecpharma.comand proceed to the News & Events/Event Calendar page under the Investors & Media heading. Please connect to the company’s website at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to listen to the webcast. A webcast replay of the conference call will also be archived onwww.fennecpharma.comfor thirty days.
About Fennec PharmaceuticalsFennec Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development and commercialization of PEDMARK to reduce the risk of platinum-induced ototoxicity in pediatric patients. Further, PEDMARK received FDA approval in September 2022 and European Commission approval in June 2023 and U.K. approval in October 2023 under the brand name PEDMARQSI. PEDMARK has received Orphan Drug Exclusivity in the U.S. and PEDMARQSI has received Pediatric Use Marketing Authorization in Europe, which includes eight years plus two years of data and market protection. For more information, please visitwww.fennecpharma.com.
For further information, please contact:
Investors:
Corporate and Media:
Source: Fennec Pharmaceuticals Inc.